Maze Therapeutics, Inc. (MAZE) Stock Statistics & Valuation Metrics

Maze Therapeutics, Inc. has a market cap or net worth of $398.98M. The enterprise value is ―.

Maze Therapeutics, Inc. has 43,796,060 shares outstanding. The number of shares has decreased by -2.65% in one year.

Maze Therapeutics, Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Maze Therapeutics, Inc. is ―. Maze Therapeutics, Inc.’s PEG ratio is ―.

In the last 12 months, Maze Therapeutics, Inc. had revenue of ― and earned ― in profits. Earnings per share was ―.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

Maze Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Maze Therapeutics, Inc. upcoming earnings date is Mar 31, 2025, TBA Not Confirmed.

Maze Therapeutics, Inc. as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Maze Therapeutics, Inc. has paid ― in taxes.

Maze Therapeutics, Inc. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Maze Therapeutics, Inc. has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Maze Therapeutics, Inc. is $25.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy